Shionogi Inc.

Shionogi Inc. is the U.S. subsidiary of Shionogi & Co., Ltd., a research-driven Japanese pharmaceutical company. Headquartered in Florham Park, New Jersey, Shionogi Inc. is dedicated to developing, partnering, and commercializing medicines that address serious unmet medical needs globally. The company's mission is to supply the best possible medicine to protect the health and well-being of the patients it serves and the society in which it operates.

Shionogi Inc. focuses on several therapeutic areas, with a significant emphasis on anti-infectives, including treatments for multidrug-resistant infections such as FETROJA® (cefiderocol). The company's pipeline also includes investigational compounds for infectious diseases, rare diseases, acute ischemic stroke, metabolic disorders, and oncology. Historically, Shionogi has been a leader in antibiotics and has expanded its portfolio to include innovative medications for HIV and influenza.

Recent notable activities for Shionogi Inc. include the launch of Zurvae capsules for major depressive disorder in March 2026 and the acquisition of global rights to the ALS treatment Radicava from Tanabe Pharma in April 2026, marking a strategic shift into rare diseases. The company also acquired significant assets from Pfizer in January 2026. Nate McCutcheon assumed the role of President and CEO of Shionogi Inc. in July 2022, leading the company's strategic expansion of its product portfolio and market presence through both organic growth and strategic acquisitions.